Business Wire

MA-EXCEL-DRYER

18.3.2021 15:54:13 CET | Business Wire | Press release

Share
The Centers for Disease Control and Prevention (CDC) Updates Handwashing Guidelines and Materials

The Centers for Disease Control and Prevention (CDC) recently updated handwashing guidelines, standardizing language and updating visuals. Though hand dryers have always been recommended by the organization, language around the topic of hand drying was inconsistent across industries and materials. Now, with the latest updates, the CDC’s stance is unequivocally clear: hand dryers are a supported hand drying solution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210318005663/en/

The CDC has shared that “germs spread more easily when hands are wet” and recommends thorough hand drying with clean towels or hand dryers to mitigate germ transfer and the spread of viruses like COVID-19. The organization’s robust hand hygiene media library now visually depicts both towels and hand dryers as a means to complete hygienic hand drying in materials supporting the Stop Germs! Wash Your Hands campaign including fact sheets , posters and other downloadable assets . Additionally, CDC hand drying FAQs and reopening guidelines across industries, including schools, make specific mention of hand dryers among recommended supplies to have on hand.

“Hand drying is a critical step of proper hand hygiene but has not received the same media attention that handwashing has throughout the pandemic,” shared William Gagnon, vice president of marketing and sales at Excel Dryer. “Ask most anyone how long you should wash your hands and they’re likely to respond with ’20 seconds’ or ‘the amount of time it takes to sing Happy Birthday twice.’ I don’t believe they realize how important hand drying is to the process and am hopeful the updated materials will help to mitigate confusion and, in turn, the virus’ spread.”

Excel Dryer’s line of sensor-activated, touchless hand dryers have long been trusted to achieve proper hand hygiene by retail stores, airports, restaurants, schools and universities, stadiums and arenas, hospitals and healthcare facilities, public safety complexes—and any commercial facility with public and/or employee restrooms.

The CDC’s updated guidelines provide peace of mind to facility managers and members of the public who will interact with hand dryers as these sites reopen.

“We encourage policy makers, owners, operators and any decision makers or organizations responsible for commercial facilities to consult the updated CDC hygiene resources when reopening guidelines are formulated,” furthered Gagnon. “In some instances, these guidelines will need to be updated to correct incorrect guidance on the use of hand dryers. The CDC has made this point clear: hand dryers are recommended.”

To review the CDC’s handwashing recommendations, visit cdc.gov/handwashing/when-how-handwashing.html . To learn more about Excel Dryer’s hygienic hand drying solutions, visit: exceldryer.com .

About Excel Dryer, Inc.
Excel Dryer has been manufacturing the finest American-made hand dryers for more than 50 years. The family-owned and -operated company revolutionized the industry with the invention of the patented XLERATOR® Hand Dryer that created the high-speed, energy-efficient hand dryer category and set a new standard for performance, reliability and customer satisfaction. Excel Dryer prides itself on offering the best customer service and making hygienic, cost-effective and sustainable products people can depend on. Available for distribution worldwide, Excel Dryer products can be purchased through an established network of sales representatives who call on more than 5,000 distributors globally. Learn more about Excel Dryer at exceldryer.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/XLERATOR/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye